Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01518751
Other study ID # KEK-ZH-NR. 2011-0077
Secondary ID
Status Completed
Phase N/A
First received January 17, 2012
Last updated September 29, 2015
Start date December 2011
Est. completion date December 2014

Study information

Verified date September 2015
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Observational

Clinical Trial Summary

Symptoms of blood pressure dysregulation, impaired swallowing and digestion are common amongst parkinson patients. The overall aim of this study is to examine blood pressure regulation and esophageal motility and gastric emptying in Parkinson`s disease (PD) patients.

The investigators hypothesize that - compared to age-matched controls - PD patients display an altered regulation of blood pressure, altered gastroesophageal motility, and delayed gastric emptying. These symptoms occur already early in the disease process, but aggravate with progression of the disease.

The investigators will perform a 7-day blood pressure measurement, measurement of central blood pressure and pulse wave velocity, assessment of pulse variability, Schellong tests to assess orthostatic function, high resolution manometry assessments during swallowing acts, and a 13C-sodium octanoate breath test to assess gastric emptying, in 18 PD patients (9 each Hoehn&Yahr stages 1,2) and 12 age- and gender-matched healthy controls. Results will be interpreted in relation to the severity of PD motor symptoms.

The investigators anticipate that blood pressure dysregulation and gastroesophageal motility disturbances will be present only in PD subjects, but not in matched controls without neurological disorders and without any extrapyramidal motor signs. Furthermore, the investigators expect to find an association between motor impairment and the severity of these autonomic symptoms, however, that according to the Braak staging, subtle disturbances must already be present in the early stages of PD.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date December 2014
Est. primary completion date December 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 50 Years to 70 Years
Eligibility Inclusion criteria: - informed, written & formal consent for participation

- male/female subjects, aged 50-70 years

- PD patients (9 subjects each in Hoehn & Yahr stage 1 & 2)

Exclusion criteria: - Antihypertensive treatment

- medication influencing gastrointestinal motility for at least the elimination half life of the drug

- medication interfering with blood-pressure regulation for at least the elimination half life of the drug

- significant systemic illness

- BMI < 18 or > 30kg/m2

- symptoms or a history of GI disease or surgery

- with any evidence of infectious disease

- evidence or history of drug or alcohol abuse

- diabetes mellitus

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland University Hospital Zurich, Neurology Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Epprecht L, Schreglmann SR, Goetze O, Woitalla D, Baumann CR, Waldvogel D. Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal. J Neurol. 2015 Aug;262(8):1946-53. doi: 10.1007/s00415-015-7799-z. E — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary orthostatic hypotension drop of systolic (=20mmHg) or diastolic (=10mmHg) blood pressure upon Schellong test during study visit No
Secondary delayed gastric emptying statistical difference in mean gastric emptying assessed via octanoate breath test during study visit No
Secondary long term blood pressure mean 7d systolic, diastolic, mean arterial blood pressure and heart rate recordings during 7d after study visit at home No
Secondary heart rate variability difference in heart rate variability or spectral analysis of heart rate variability? during study visit No
Secondary arterial stiffening difference in pulse wave velocity and augmentation index calculation from applanation tonometry recordings? during study visit No
Secondary oesophageal motility high-density manometry to measure aspects of oesophageal motility during study visit No
Secondary subjective symptoms of gastrointestinal and cardiovascular dysfunction validated questionnaires: Fraser, 2007, p14133; Stanghellini, 1996, p14183; Revicki, 2003, p13823; Kaufmann, 2012, p13817; } during study visit No
Secondary Clinical assessment UPDRS part III and MoCA score (Nasreddine, 2005, p14186) during study visit No